In a target trial emulation using N3C data, adults prescribed metformin within six days of SARS-CoV-2 infection had about half the risk of long COVID or death within six months.
|Videos|May 19, 2020
Contagion Live News Network: Coronavirus Briefing for May 19, 2020
Author(s)Contagion® Editorial Staff
A daily news update on our COVID-19 coverage.
Advertisement
Hello and thank you for joining Contagion. I’m assistant editor Grant Gallagher, here with an infectious disease news brief.
Researchers and epidemiologists are working tirelessly to understand clusters that shed new insight into transmission dynamics.A recent CDC Morbidity and Mortality Weekly Report or “MMWR” focused on
Today we also shared an interview with Dr. Adam Brufsky, an oncologist who has worked with infectioius disease researchers to contribute new theories on COVID. In this second part of our interview, Dr. Brufsky moves from talking about glycosolation of the SARS-CoV-2 spike protein to emerging evidence about the potential for multiple strains of the coronavirus.
And as a reminder, yesterday we shared an interview with Dr. Armand Balboni, CEO of a biotechnology company that’s working with FUJIFILM Toyama Chemical on its favipiravir treatment, which is approved in Japan as an antiviral, on a new front for the drug — the global search for a pandemic treatment that can both prevent and combat COVID-19
For more on these stories and other infectious disease news, visit contagionlive.com.
Advertisement
Related to this article
Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Half of Long COVID Patients Substantially Improve Within 3 years
3
Early Metformin Linked to 53% Lower Risk of Long COVID or Death
4
From Pathogen to Infectious Disease Diagnosis: Reflex Testing Targets Hepatitis D Gap
5